Cargando…
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607927/ https://www.ncbi.nlm.nih.gov/pubmed/28966662 http://dx.doi.org/10.1177/1756285617721093 |
| _version_ | 1783265363370180608 |
|---|---|
| author | Schneider-Gold, Christiane Reinacher-Schick, Anke Ellrichmann, Gisa Gold, Ralf |
| author_facet | Schneider-Gold, Christiane Reinacher-Schick, Anke Ellrichmann, Gisa Gold, Ralf |
| author_sort | Schneider-Gold, Christiane |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5607927 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56079272017-10-01 Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience Schneider-Gold, Christiane Reinacher-Schick, Anke Ellrichmann, Gisa Gold, Ralf Ther Adv Neurol Disord Letter to the Editor SAGE Publications 2017-07-26 2017-10 /pmc/articles/PMC5607927/ /pubmed/28966662 http://dx.doi.org/10.1177/1756285617721093 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Schneider-Gold, Christiane Reinacher-Schick, Anke Ellrichmann, Gisa Gold, Ralf Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title | Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title_full | Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title_fullStr | Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title_full_unstemmed | Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title_short | Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience |
| title_sort | bortezomib in severe musk-antibody positive myasthenia gravis: first clinical experience |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607927/ https://www.ncbi.nlm.nih.gov/pubmed/28966662 http://dx.doi.org/10.1177/1756285617721093 |
| work_keys_str_mv | AT schneidergoldchristiane bortezomibinseveremuskantibodypositivemyastheniagravisfirstclinicalexperience AT reinacherschickanke bortezomibinseveremuskantibodypositivemyastheniagravisfirstclinicalexperience AT ellrichmanngisa bortezomibinseveremuskantibodypositivemyastheniagravisfirstclinicalexperience AT goldralf bortezomibinseveremuskantibodypositivemyastheniagravisfirstclinicalexperience |